Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are willing and able to give written consent to take part in the study.
• You are a woman aged 18 or older at the time of signing the consent form.
• You have been diagnosed (confirmed by tissue testing) with high-grade serous carcinoma of the ovary, fallopian tube, or peritoneum (the lining of the abdomen).
• Your cancer came back or got worse between 1 and 6 months after finishing a platinum-based chemotherapy treatment (of at least 4 cycles), meaning it is considered "platinum-resistant."
• You have had no more than 5 cancer treatments in total, and no more than 2 treatments after your cancer was found to be platinum-resistant.
• You have at least one tumour that can be measured on a scan using standard methods.
• You are in good general health and able to carry out daily activities with no or only minimal limitations (confirm with trial site).
• Your doctor estimates you are expected to live for at least 3 more months.
• A tumour tissue sample (either stored from before or newly collected) is available or can be obtained during the screening period.
• Any side effects from previous treatments have mostly resolved or are stable.
• Your blood counts, liver, kidney, and blood clotting levels are within acceptable ranges, tested within 5 days before starting treatment.
• You are not pregnant, not breastfeeding, and either cannot become pregnant or agree to use reliable contraception during the study and for 3 months after the last dose.

Who may not be able to join:

• You have had major surgery or a serious injury within the past 28 days, or a diagnostic biopsy within the past 14 days before starting treatment.
• You have received other cancer treatments (including chemotherapy, targeted therapy, or immunotherapy) too recently before the start of the study (timeframes vary by treatment type — confirm with trial site).
• You have had radiotherapy within the past 14 days before starting treatment.
• You have previously been treated with a FAK inhibitor or with a drug called pegylated liposomal doxorubicin (PLD).
• You have had a different type of cancer in the past 3 years, unless it was fully cured (for example, certain types of early-stage cervical cancer may be allowed — confirm with trial site).
• You have active cancer that has spread to the brain or the lining around the brain.
• You have had a serious heart, stroke, or blood clot condition in the past 6 months, or you currently have certain heart problems such as irregular heartbeat, uncontrolled high blood pressure, reduced heart pumping function, or other significant heart issues (confirm with trial site).
• You have uncontrolled fluid build-up around the lungs, heart, or in the abdomen that requires repeated draining (a small amount of fluid visible only on scans may be acceptable — confirm with trial site).
• You have difficulty swallowing or absorbing oral (by mouth) medications.
• You have serious uncontrolled gut conditions such as active Crohn's disease, active ulcerative colitis, or uncontrolled gastrointestinal bleeding.
• You have an active infection that requires treatment with medicines throughout your body within the past 14 days.
• You have a known HIV infection.
• You have known active Hepatitis B or Hepatitis C infection.
• You have any other condition, ongoing treatment, or abnormal test result that the investigator believes would make it unsafe or unsuitable for you to participate.
• You have a known psychiatric condition or substance use problem that would make it difficult to follow the study requirements.
• You have a known allergy or serious reaction to the study drugs (IN10018 or PLD) or any of their ingredients.
• You have previously received a high cumulative dose (550 mg/m² or more) of a type of chemotherapy called anthracycline (confirm with trial site).
• You are currently taking, or plan to take, certain medications that strongly affect how specific liver enzymes or drug transporters work, within 14 days before starting the study (confirm with trial site for specific drug names).

Important: Always verify eligibility with the trial site directly before applying.